You are here

Articles

CML Therapy: Making History, Making Progress. LLS interviews Brian J. Druker MD. March 2008

published: 19 May 2008

New Techniques Enabling a Greater Understanding of the Science and Biology of Leukemia: Interview With Dr. Brian Druker

published: 27 April 2008

EUTOS - The European Treatment Outcome Study

published: 11 April 2008

Medical News Today report that SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).

published: 27 March 2008

Update on NICE approval of dasatinib/nilotinib plus template letter for MP

published: 27 February 2008

Targeted Therapy in Chronic Myeloid Leukemia

published: 16 February 2008

ePatients: Engaging Patients in Their Own Care

published: 6 February 2008

ASH 2007- New Therapeutic Options in CML and What They Mean for Patients:

published: 6 February 2008

AWMSG recommends SPRYCEL® for use in NHS Wales. Welsh guidance goes further than the SMC

published: 21 January 2008

Webcast- "Monitoring and Adherence in CML"

published: 18 January 2008

Household Exposure to Pesticides and Risk of Childhood Hematopoietic Malignancies: The ESCALE Study (SFCE)

published: 17 January 2008

Omacetaxine active against T3125i mutation in CML

published: 8 January 2008

SKI606- Bosutinib

published: 8 January 2008

OHSU Cancer Institute researchers have found a new candidate to treat resistant forms of CML

published: 8 January 2008

6th National Seminar for CML Patients - Edinburgh Nov. 2007

published: 2 January 2008

Template letter to your MP regarding NICE appraisal of Dasatinb and Nilotinib

published: 8 November 2007

Update on Primary Therapy, Second-Line Therapy, and New Agents for Chronic Myelogenous Leukemia

published: 7 November 2007

ENACT - AMN 107 Trials. Click here to view list of centres open and recruiting.

published: 8 October 2007

EMEA approval of Tasigna expected by November 2007

published: 29 September 2007

EMEA approve 100mg as recommended starting dose of Sprycel for chronic phase CML

published: 29 September 2007